SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-22-056442
Filing Date
2022-05-05
Accepted
2022-05-05 16:06:10
Documents
61
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20210930x10q.htm   iXBRL 10-Q 1022637
2 EXHIBIT 31.1 cldx-20210930xex31d1.htm EX-31.1 13975
3 EXHIBIT 31.2 cldx-20210930xex31d2.htm EX-31.2 13274
4 EXHIBIT 32.1 cldx-20210930xex32d1.htm EX-32.1 7964
  Complete submission text file 0001104659-22-056442.txt   5145924

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cldx-20210930.xsd EX-101.SCH 29108
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cldx-20210930_cal.xml EX-101.CAL 42332
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cldx-20210930_def.xml EX-101.DEF 138640
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20210930_lab.xml EX-101.LAB 325120
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20210930_pre.xml EX-101.PRE 240522
55 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20210930x10q_htm.xml XML 1036280
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 22896164
SIC: 2835 In Vitro & In Vivo Diagnostic Substances